NAD+ + GHK-Cu Anti-Aging Protocol

NAD+ levels decrease significantly with age, dropping roughly 50% between the ages of 40 and 60 in human tissues. This decline impairs sirtuin function, DNA repair capacity, and mitochondrial efficiency. Research suggests that restoring NAD+ levels can reactivate many of these age-suppressed pathways.

GHK-Cu is a naturally occurring tripeptide that is abundant in young plasma but declines with age. Research has demonstrated its ability to modulate the expression of over 4,000 genes, with many involved in collagen production, wound healing, stem cell function, and antioxidant defense. It represents a unique approach to anti-aging at the gene expression level.

NAD+ addresses intracellular aging mechanisms (mitochondrial function, DNA repair, sirtuin activation) while GHK-Cu operates at the extracellular and gene expression level (collagen remodeling, stem cell signaling, tissue architecture). The combination creates a multi-layered approach that single-compound protocols cannot achieve.

Published studies on NAD+ supplementation typically observe measurable biomarker changes within 4-6 weeks, while GHK-Cu collagen synthesis effects have been documented over 8-12 weeks. A 12-16 week protocol allows both compounds adequate time to demonstrate their full research potential.

Both NAD+ and GHK-Cu are naturally occurring compounds with favorable safety profiles in published research. Several longevity studies have administered NAD+ precursors over 6-12 month periods with no adverse effects reported. However, all extended research protocols should follow institutional guidelines and appropriate oversight.